1 Whereas estrogen may protect against the onset and incidence of psychosis in the illness, the neurobiological effects of the ovarian steroid remain unclear.
Increasing evidence now suggest that estrogen may play a protective role against the onset and incidence of psychosis in schizophrenia. In women, the onset of schizophrenia occurs far later than it does in men and there is a peak incidence of the illness after menopause. [2] [3] [4] Moreover, estrogen supplements given together with antipsychotic drugs improve clinical outcomes. 6 One of the theories postulates that estrogen induces neurons in critical regions of the brain to respond favourably to dopamine in a manner not yet understood. This is consistent with the 'Dopamine Hypothesis' of schizophrenia, which postulates an overactivity of dopamine neurons or heightened responsiveness of D 2 receptors to dopamine or both may play an important role in positive symptoms of the illness. 7, 8 Recent evidence from PET scan studies further suggests that reduced abundance or underfunction of D 1 D 5 receptors or both in the prefrontal cortex may link to the negative symptom of schizophrenia. 1 Taken together, it now appears that an overactivity of D 2 -like receptors and an underactivity of D 1 -like receptors or both may underlie the pathophysiology of the illness. This notion is substantiated by clinical observations as anti-psychotic drugs that block D 2 receptors are effective in alleviating positive symptoms, 9, 10 whilst those enhancing the activity of D 1 -like receptors may improve negative symptoms. 11 Recently, we have reported that estrogen selectively augments the expression of D 5 receptors, a member of the D 1 -like receptor family, but not D 1 receptors, in central neurons. 5 Interestingly, D 5 receptors are constitutively active and play an important role in maintaining functional activities of the host cells through the cAMP pathway. 12 The possibility that this neurobiological effect of estrogen on D 5 receptors may affect critical regions of the brain and confer protection against psychosis in schizophrenia needs to be considered. However, besides estrogen, mammalian ovaries also produce another important ovarian steroid, progesterone. In women, progesterone and estrogen are produced and released from ovaries in a sequential manner during the menstrual cycle. The two steroids interact at many levels to induce neurophysiological changes pertinent to behavioural modification. 13, 14 Unlike estrogen, the role of progesterone in modulating dopamine responsiveness in central neurons, however, remains elusive.
Employing a well characterised long-term rat hypothalamic cell culture system, we have recently identified that atrial natriuretic factor (ANP)-producing neurons constitute a common convergent site for integration of ovarian steroid and dopamine actions. 5 In this system, estrogen induces the expression of progesterone receptors in ANP neurons and augments neuronal functions by increasing the expression of constitutively active D 5 receptors that generate cAMP in a ligand-independent manner. Adopting the same approach, we have now exploited our hypothalamic culture system to examine the effect of progesterone, alone and in conjunction with estrogen, in modulating the expression of D 5 receptors and the function of ANP neurons.
In rat hypothalamic neuron cultures, 15, 16 over a wide range of concentrations (10 −12 to 10 −8 M), progesterone alone did not induce significant changes in ir-ANP release ( Figure 1 ). However, treatment with estrogen (10 −14 to 10 −11 M), increased ir-ANP secretion in a dose- 
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To evaluate whether progesterone might also modulate the production of ANP and estrogen-mediated changes in ANP production, the pro-ANP mRNA of the cultures treated with the steroids were subjected to Northern blot analysis. In this series of studies, hypothalamic cultures were treated in the same manner as described in the release studies. The intensity of bands for pro-ANP mRNA signals in each lane was standardized to that of GAPDH mRNA, a constituent housekeeping gene. This was done by stripping the ANP mRNA band from the membrane and reprobing with GAPDH antisense oligonucleotides ( Figure 3 ). Figure 3a shows that estrogen treatment enhances the abundance of pro-ANP mRNA in a dose-related manner, in the range of concentrations from 10 −14 to 10 −10 M. Whereas by itself, progesterone did not affect the basal level of pro-ANP mRNA, the bar graph in Figure 3b shows that 10 −8 M of the steroid potentiates estrogen-induced increment of pro-ANP mRNA signals (P Ͻ 0.01). It is noteworthy that this increasing effect of progesterone was also blocked by co-incubation with 10 −6 M of SCH23390, a D 1 -like receptor antagonist ( Figure 3 ). The specificity of the Northern blot analysis was established by demonstrating that replacement of the antisense probes with sense oligonucleotides in the same studies completely abolished the detection of the pro-ANP mRNA signal (data not shown). In addition, we have reported previously that whereas SCH-23390 alone has no effect on the function of ANP neurons, the antagonist markedly suppressed the stimulated release of ir-ANP and pro-ANP mRNA expression induced by estrogen over the range of 10 −12 to 10 −10 M of the steroid. 5 To determine whether progesterone might also affect dopamine receptor expression, we examined mRNA abundance for D 5 Similar to what has been described for the release and production of ANP, progesterone alone failed to produce any significant effect, whilst estrogen treatment augmented the abundance of D 5 receptor mRNA in hypothalamic cultures, in a dose-related manner (Figure 4b) . Furthermore, consistent with the release studies, estrogen-augmented levels of D 5 receptor mRNA abundance were further enhanced by 10 −8 M of progesterone supplement (P Ͻ 0.01) (Figure 4b) .
In our present studies, we have shown that whereas progesterone alone fails to modulate the basal release of ir-ANP, the steroid markedly enhances the stimulatory effect of estrogen on ir-ANP release and pro-ANP mRNA abundance. The simplest explanation for this enigmatic observation is that in untreated cultures, ANP neurons do not possess progesterone receptors and remain innate to the steroid. Estrogen treatment induces the expression of progesterone receptors in the neurons, which in turn allow the cells to respond appropriately to progesterone. This sequence of biological events has been described in detail in our earl- ier studies reported elsewhere. 5 In the previous studies, a triple staining technique was exploited by combining immunocytochemistry and in situ hybridization to confirm the co-localization of progesterone and estrogen receptors in ANP neurons treated with and without estrogen. As the majority of ANP neurons in cultures have been shown to possess progesterone receptors after estrogen treatment, most of the neurons in our cultures are regarded as progesterone-sensitive. In our present studies, progesterone is therefore considered to exert a direct effect on ANP neurons. This concentration of progesterone (10 −8 M) is consistent with that of the steroid required to affect a variety of progesterone-regulated functions in various biological systems and is similar to the binding affinity of progesterone receptors for the steroid. 18, 19 Previously, we have shown that estrogen induces ir-ANP release and pro-ANP mRNA expression in hypothalamic cultures. These effects are mediated through an up-regulation of cAMP production involving an augmented expression of D 5 , but not D 1 receptors, in ANP neurons. 5 It is important to point out that unlike D 1 receptors, D 5 receptors are auto-active and capable of generating cAMP in a ligand-independent manner. 12 Taking the above discussion into consideration, the effect of progesterone described here is likely to be mediated through the same mechanism as that found in estrogen studies. Several lines of evidence support this interpretation. First, in the present studies, progesterone is shown to further enhance estrogenaugmented D 5 receptor mRNA expression. Secondly, SCH23390, a D 5 receptor antagonist, effectively blocks the augmenting effect of progesterone on estrogenmediated changes of ANP release and production. Furthermore, this augmenting effect of progesterone on estrogen-mediated changes involves the cAMP-dependent protein kinase A system, as the combined steroid treatment is also blocked by Rp-cAMP, a competitive antagonist to cAMP (data not shown).
Our present observations have some broad implications. It confirms that ovarian steroids and dopamine share a common convergent pathway in the brain and have identified hypothalamic ANP neurons as one of the common sites of the interaction in this relay. This is consistent with earlier reports that in estrogenprimed female rats, activation of D 1 -like receptors or the cAMP-dependent protein kinase A pathway produces behavioral effects similar to that induced by progesterone. 14 In this context, our present findings do bear behavioral relevance and have identified D 5 receptors as playing a central role in integrating the actions of the ovarian steroids and of dopamine in the brain.
Hypothalamic ANP neurons are known to play an important role in water regulation, as the neuropeptide is a potent inhibitor of drinking behavior. 20 Hypofunctions of these neurons have been implicated in the pathophysiology of excess water drinking or polydipsia, a symptom that is commonly seen in chronic schizophrenia. 21, 22 As such, the effects of the ovarian steroid on ANP neurons may not be directly associated with the mechanism underlying positive and negative symptoms of the illness. However, it raises the possibility that the steroids may also interact in a similar manner to augment D 5 receptor expression in critical regions of the brain, such as the prefrontal cortex. The latter is closely linked to the pathophysiology of the negative symptoms of schizophrenia. Further studies to demonstrate that the two steroids may exert the same effects on dopamine-responsive neurons in prefrontal cortex, for example, pyramidal cells, 23 are therefore warranted.
In summary, taken together with findings from our earlier studies of estrogen, 5 we have now characterised the roles of the two important ovarian steroids, estrogen and progesterone, in their modulation of dopamine responsiveness in central neurons. Our findings suggest that whereas by itself, progesterone has little effect, the steroid is capable of further augmenting estrogen-mediating changes through the enhancement of D 5 receptors expression. The present observations raise the possibility that progesterone may be considered a beneficial adjunct to estrogen in enhancing the protection against psychotic incidences and the two steroids may be given together with antipsychotic Molecular Psychiatry drugs to further enhance therapeutic efficacy 6 in patient management.
Methods

Cell cultures
Neonatal rat hypothalamic cultures were prepared [24] [25] [26] by enzymatic dispersion of hypothalami removed from 2 to 3-day-old Sprague-Dawley rat pups. The dispersed cells were maintained in Hepes buffered Dulbecco's Modified Eagle's Medium (HDME) supplemented with 8% fetal calf serum at 37°C in 10% CO 2 . All release studies were conducted on the 7th day of culture and extended over a period of 4 days. The drugs were applied every 24 h to the cultures. Four hours after the last application of vehicle or drugs, conditioned media were removed and extracted for immunoreactive (ir) ANP release measurement by double antibody radioimmunoassay (RIA). [27] [28] [29] Each of the experiments was performed at least three times; within a study, the results of an individual condition represented the average of 3-4 cultured wells. Results presented here are the mean of three or more separate experiments from different batches of cell preparations.
Northern blot analysis
Following treatment, cells were lysed in the well by adding 0.5 ml of Trizol Reagent (Life Technologies, Grand Island, NY, USA). The cell lysate from three individual wells, each with 10 6 cells, was harvested by pipeting and pooled together as a single sample for the study. The cytoplasmic RNA was further extracted by chloroform and precipitated with isopropyl alcohol. Twelve micrograms of total RNA from each of the samples fractionated by electrophoresis through formaldehyde-agarose gel were transferred to nylon membrane and hybridized with digoxigenin-labeled ANPantisense oligonucleotide probes [30] [31] [32] and visualized by colorimetric reaction. The signals of individual bands for pro-ANP mRNA were measured as integrated intensity by a computer based Image-Pro Plus version 3 (Media Cybernetics, Silver Spring, MD, USA), taking the vehicle-treated controls as 100% for statistical comparison. After signal analysis, the same blots were reprobed with digoxigenin-labeled GAPDH mRNA oligonucleotides. The integrated intensity of each band of pro-mRNA from various treatment groups was adjusted to that of corresponding bands of GAPDH mRNA; the values were then expressed as a percentage of that of the vehicle-treated controls.
RT-PCR
The expression of D 5 mRNA in the hypothalamic cultures was determined using reverse transcription and PCR techniques. 17 The rat D 5 cDNA sequences were obtained from Gene-Bank under sequence number M69118. The 5Ј sense primer for PCR amplification of D 5 cDNA (5Ј-GGCTGGGATTACAGAGGCAACTGG) is located at bases 734-757 of the sequence, and the 3Ј antisense primer (5Ј-TCTCCTTCTTGATGGACGCTC GC) is complementary to bases 1527-1549. PCR with this primer pair produced 816-bp fragments from rat genomic DNA (not shown) and cDNA generated from RNA extracts. For GAPDH RT-PCR, PCR primers were designed according to two published rat GAPDH cDNA sequences of the same length with 98.3% sequence identity (Gene-Bank Number X02231/X00972 and M17701). 33, 34 The 5Ј sense primer (5Ј-GTGATGCT GGTGCTGAGTATGTCG) is located at bases 328-351 of the sequence, and the 3Ј antisense primer (5Ј-GTGGATGCAGGGATGATGTTCTGG) is complementary to bases 674-697. PCR with these primers produced 370-bp fragments of GAPDH from rat cDNA made from RNA extracts.
Hypothalamic cultures were treated with various drugs for 4 days. Following treatment, cells were lysed by Trizol (see Northern blot analysis) and extracted by chloroform and precipitated with isopropyl alcohol. The possible contamination of DNA was excluded by incubation with RNAase-free DNAase (Boehringer Mannheim, Postfach, Mannheim, Germany) in 1 g l −1 DNAase digestion buffer (140 mM sodium chloride, 10 mM magnesium chloride, 10 mM Tris, 1 mM dithiothreitol, pH 8.0) for 30 min at 37°C and phenol extracted. The cytoplasmic RNA samples were then reverse transcripted with Superscrip Preamplification System (Boehringer) in a total volume of 20 l using 0.001 of oligo(dT) for 60 min at 42°C. Two microlitres each of the cDNA samples were added to a PCR reaction mixture containing 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris, 50 M dNTPs, 20 pmol of the sense and antisense primers for the D 5 receptor in a total volume of 50 l. Five pmol of the sense and antisense primers for GAPDH, used as an internal control, were also added to the reaction mixture. The mixtures were overlayed with 75 l of mineral oil and heated to 99°C for 5 min; 1.25 U Taq polymerase (Boehringer) was added to each mixture. The reaction series were initiated on a Perkin-Elmer/Cetus Thermal Cycler (Norwalk, CT, USA) (95°C for 1 min, 59°C for 1 min, 72°C for 1 min, 30 cycles). A 7-min incubation at 72°C was added at the end to ensure complete extension. A negative control experiment was performed by omitting reverse transcriptase in the cDNA synthesis reaction. To draw a standard curve, reverse transcriptions were carried out from total RNA extracted from 0.06 to six vehicle-treated wells (0.25-24 g). The amplification curve was linear between 0.5 and 12 g total RNA for both D 5 and GAPDH. However, in the case of GAPDH, the linearity approached plateau phase because of a relatively higher abundance of GAPDH in the extract. Consequently, for quantitative analysis, reverse transcriptions were carried out with total RNA extracted from one well (ෂ4 g) from each of the treated groups.
Aliquots of the amplified DNA samples were loaded onto agarose gels and fractionated; a single lane in each gel contained a DNA molecular weight marker VI (Boehringer). The gels were transferred onto nylon membrane and cut into two parts according to their molecular sizes. The membrane with higher molecular weight bands was hybridized with 24-mer digoxigeninlabeled antisense oligonucleotide probes complementary to D 5 cDNA (5Ј-TGGCAGCACACACTAGCAC GTTCC, 857-880). The second part of the membrane with lower molecular weight bands was hybridized with 24-mer digoxigenin-labeled antisense oligonucleotide probes complementary to rat GAPDH cDNA (5Ј-GCCATCCACAGTCTTCTGAGTGGC, 612-635). The hybridization signals were detected with similar methods as described in Northern blot analysis. The signals of individual band for RT-PCR D 5 receptors measured as integrated optical densities by the ImagePro Plus version 3, were further standardized against those of GAPDH for comparison.
